Avastin bevacizumab: Additional Phase III data

Additional follow-up data from 647 evaluable patients with neovascular AMD who completed the in the double-blind, U.S. Phase III CATT trial showed that intravitreal Lucentis ranibizumab did not lead to a significant improvement in mean visual acuity at 5.5 years (57.7 letters vs. 60.2 letters, p=0.19) or change in visual acuity from baseline at 5.5 years (3.3 letters vs. 4.5 letters, p=0.17) vs. intravitreal Avastin. Patients received monthly Lucentis or Avastin bevacizumab for 2

Read the full 746 word article

User Sign In